M. Nauck

Endocrinology, Diabetes and Metabolism · 2006–2020

A researcher in the Science corpus: 15 papers; trusts 3 researchers and is trusted by 7 researchers here, as inferred from the citation graph.

Subfields

• Endocrinology, Diabetes and Metabolism — 184 citations into it; #110 of 623 by trust here, #79 by citations
• Surgery — 93 citations into it; #215 of 1,106 by trust here, #328 by citations
• Molecular Biology — 67 citations into it
• Oncology — 16 citations into it; #559 of 1,698 by trust here, #1,023 by citations

Whom M. Nauck trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. J. Drucker
2. Jens J. Holst
3. John B. Buse
4. Ralph DeFronzo
5. J. Meier

Who trusts M. Nauck overall

1. Wook Kim
2. J. Meier
3. Ralph DeFronzo
4. Josephine M. Egan
5. D. J. Drucker
6. Jens J. Holst
7. Renee E. Amori
8. S. Swallow

Papers from M. Nauck's perspective

Ordered by how strongly the researchers M. Nauck trusts endorse each paper. Same corpus, a different order for every researcher.

1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (New England Journal of Medicine)
2. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. (The Lancet)
3. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. (Diabetes)
4. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (Nature Medicine)
5. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. (Journal of Medicinal Chemistry)
6. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (Journal of Clinical Investigation)
7. The physiology of glucagon-like peptide 1. (Physiological Reviews)
8. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes… (Diabetes Care)
9. Inhibition of gastric inhibitory polypeptide signaling prevents obesity (Nature Medicine)
10. The Molecular Biology of Memory Storage: A Dialogue Between Genes and Synapses (Science)

Their papers

• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014) — 2,951 citations
• Incretin hormones: Their role in health and disease (2018) — 781 citations
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020) — 1,289 citations
• COVID-19 and diabetes mellitus: from pathophysiology to clinical management (2020) — 846 citations
• Glucagon-like peptide 1 (GLP-1) (2019) — 1,265 citations
• Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. (2018) — 596 citations
• Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. (2018) — 1,439 citations
• Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015) — 732 citations
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2013) — 2,521 citations
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012) — 3,782 citations
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. (2010) — 610 citations
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes (2008) — 829 citations
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial (2007) — 674 citations
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. (2006) — 3,807 citations
• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes (2006) — 1,290 citations